drugset
drugset / Trial / NCT05099549

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

NCT05099549 ↗

Phase 1/2 Terminated 11 enrolled NKGen Biotech, Inc. Affimed GmbH · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.

Timeline

Start
2021-11-03
Primary completion
2023-09-21
Completion
2023-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject AFM24 Unknown — —
Subject TROCULEUCEL Cell therapy — Intravenous

Indications

colorectal neoplasm head and neck squamous cell carcinoma metastatic neoplasm non-small cell lung carcinoma refractory malignant neoplasm